Hib-DTP-hepatitis B-poliovirus vaccine (Easysix) - Panacea Biotec

Drug Profile

Hib-DTP-hepatitis B-poliovirus vaccine (Easysix) - Panacea Biotec

Alternative Names: Easysix; Fully liquid hexavalent DTwP-HepB-Hib-IPV vaccine - Panacea Biotec; Temperature-stable vaccine (Hib-DTP-hepatitis B-poliovirus vaccine) - Panacea Biotec

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacea Biotec
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Sep 2016 Panacea Biotech plans a phase II/III trial Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus infections and Poliomyelitis (In infants, Prevention) in India (CTRI2015-02-005578)
  • 22 Dec 2010 Panacea Biotec completes a phase I trial of Easysix™ in healthy infants aged 15-18 months for Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus infections and Poliomyelitis in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top